Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadroparin for VTE and ATE Prevention in Cancer Patients (PROTECHT)
NCT00951574Phase 3Completed
- Sponsor
- Italfarmaco
- Start
- Oct 2003
- Primary completion
- May 2007
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nadroparin in venous thromboembolism (VTE), arterial thromboembolism, sponsored by Italfarmaco. Started Oct 2003; status: completed.
02
Drugs
nadroparin
03
Conditions
venous thromboembolism (VTE)arterial thromboembolism
Beyond the preview
Go deeper on NCT00951574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951574.